AKT-induced tamoxifen resistance is overturned by RRM2 inhibition

Molecular Cancer Research

Volumn 12, Issue 3, 2014, Pages 394-407

  Shah, Khyati N ^a   Mehta, Kshama R ^b   Peterson, David ^c   Evangelista, Marie ^c   Livesey, John C ^a   Faridi, Jesika S ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; PROTEIN KINASE B; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ISOENZYME; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE STUDY; RNA INTERFERENCE; TUMOR GROWTH; VALIDATION STUDY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; ISOENZYMES; MCF-7 CELLS; MICE; NEOPLASMS, HORMONE-DEPENDENT; PROTO-ONCOGENE PROTEINS C-AKT; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; SIGNAL TRANSDUCTION; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897039699     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0219     Document Type: Article

References (43)

1. American Cancer Society. Cancer facts & figures 2013. Atlanta, GA: American Cancer Society; 2013.
2. Dowsett M. Estrogen receptor: methodology matters. J Clin Oncol 2006;24:5626-8. (Pubitemid 46631300)
3. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32. (Pubitemid 26168699)
4. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003;86:477-86. (Pubitemid 37412587)
5. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007;7:46-53. (Pubitemid 46020846)
6. Peto R, Boreham J, Clarke M, Davies C, Berai C. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
7. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008;9:239.
8. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61. (Pubitemid 36395255)
9. Arpino G, De Angelis C, Giuliano M, Giordano A, Falato C, De Laurentiis M, et al. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. Oncol 2010;77:23-37.
10. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16. (Pubitemid 32880059)
11. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-17.
12. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447s-54s. (Pubitemid 36105786)
13. Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, et al. Activation of akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat 2013;137:397-406.
14. Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Ellis IO, Green AR. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat 2011;127:407-16.
15. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005;207:139-46. (Pubitemid 41404144)
16. Spears M, Cunningham CA, Taylor KJ, Mallon EA, Thomas JS, Kerr GR, et al. Proximity ligation assays for isoform- specific akt activation in breast cancer identify activated Akt1 as a driver of progression. J Pathol 2012;227:481-9.
17. Péerez-Tenorio G, Stål O, Arnesson LGSoutheast Sweden Breast Cancer Group. Activation of Akt/PKBin breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002;86:540-5. (Pubitemid 34185089)
18. Coser KR, Chesnes J, Hur J, Ray S, Isselbacher KJ, Shioda T. Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc Natl Acad Sci U S A 2003;100:13994-9. (Pubitemid 37499179)
19. Tihan T, Elford HL, Cory JG. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4- dihydroxybenzamidoxime. Adv Enzyme Regul 1991;31:71-83.
20. Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle 2005;4:269-78. (Pubitemid 41365334)
21. Faridi JS, Mohan S, De Léon DD. Modulation of cathepsin D routing by IGF-II involves IGF-II binding to IGF-II/M6P receptor in MCF-7 breast cancer cells. Growth Factors 2004;22:169-77. (Pubitemid 39377909)
22. Faridi J, Fawcett J, Wang L, Roth RA. Akt promotes increased mammalian cell size by stimulating protein synthesis and inhibiting protein degradation. Am J Physiol Endocrinol Metab. 2003;285:E964-72. (Pubitemid 37296317)
23. Shah KN, Faridi JS. Estrogen, tamoxifen, and akt modulate expression of putative housekeeping genes in breast cancer cells. J Steroid Biochem Mol Biol 2011;125:219-25.
24. Rhodes DR, Yu J Deshpande N, Varambally R, Ghosh D, Barrette T, Shanker K, et al. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6. (Pubitemid 38391943)
25. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
26. Zhao H, Langerød A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004;15:253-36.
27. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27. (Pubitemid 351655218)
28. Faridi J, Wang L, Endemann G, Roth RA. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 2003;9:2933-9. (Pubitemid 36993252)
29. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63. (Pubitemid 47525152)
30. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-71. (Pubitemid 41032603)
31. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal- like human breast cancer. Cancer Cell 2006;9:121-32. (Pubitemid 43202662)
32. Glück S, Ross JS, Royce M, McKenna EFJr, Perou CM, Avisar E, et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat 2012;132:781-91.
33. D'Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 2012;149:1023-34.
34. Rahman MA, Amin AR, Wang D, Koenig L, Nannapaneni S, Chen Z, et al. RRM2 regulates bcl-2 in head and neck and lung cancers: A potential target for cancer therapy. Clin Cancer Res 2013;19:3416-28.
35. Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: A marker for DNA damage. Methods Mol Biol 2012;920:613-26.
36. Veale D, Carmichael J, Cantwell BM, Mannix KA, Elford HL, Blackie R, et al. A phase 1 and pharmacokinetic study of didox: A ribonucleotide reductase inhibitor. Br J Cancer 1988;58:70-2.
37. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, et al. Enhanced NFkB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007;7:59.
38. Fan H, Villegas C, Wright JA. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci U S A 1996;93:14036-40. (Pubitemid 26424241)
39. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004;23:1539-48. (Pubitemid 38406516)
40. Huang L, Zhao S, Frasor JM, Dai Y. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoSONE2011;6:e22274.
41. Wozniak K, Kolacinska A, Blasinska-Morawiec M, Morawiec-Bajda A, Morawiec Z, Zadrozny M, et al. The DNA-damaging potential of tamoxifen in breast cancer and normal cells. Arch Toxicol 2007;81:519-27. (Pubitemid 47012471)
42. Raje N, Kumar S, Hideshima T, Ishitsuka K, Yasui H, Chhetri S, et al. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. Br J Haematol 2006;135:52-61. (Pubitemid 44337662)
43. Rubens RD, Kaye SB, Soukop M, Williams CJ, Brampton MH, Harris AL. Phase II trial of didox in advanced breast cancer. Cancer research campaign phase I/II clinical trials committee. Br J Cancer 1991;64:1187-8.